皮奥格利塔治疗增加了细胞酸可变和与蛋白质结合的硫硫分离物

相关实验视频

Updated: Jul 27, 2025

11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.5K

Mohammad Z Islam¹, Rodney E Shackelford²

¹Department of Pathology & Translational Pathobiology, LSU Health Sciences Center Shreveport, Shreveport, LA, 71130, United States.

Biochemical and biophysical research communications

|June 7, 2023

概括

药物皮奥格利塔能增强铁硫集群和硫合成,有利于缺少ATM蛋白信号的细胞,特别是患有心血管疾病的细胞. 这揭示了pioglitazone的新疗法作用.

科学领域:

生物化学生化学
细胞生物学细胞生物学
药理学药理学是指药理学的学科.

背景情况:

铁硫集群对于细胞功能和心血管健康至关重要,是细胞硫化池的一部分.
ATM蛋白调节铁硫团,其信号传递可能在心血管疾病中受到损害.
皮奥格利塔与ATM蛋白信号共享细胞效应,促使人们对其对铁硫团形成的影响进行调查.

研究的目的:

为了研究皮奥格利塔对细胞铁硫团形成的影响.
评估皮奥格利塔对细胞硫化物概况,氧化还原状态和在ATM蛋白存在或不存在时的DNA损伤的影响.

主要方法:

检查了皮奥格利塔对细胞总硫化物概况,谷氨氧化还原状态和囊氨酸玛酶活性的影响.
在皮奥格利塔治疗后,在具有或没有ATM蛋白表达的细胞中评估了双链DNA断裂的形成.

主要成果:

皮奥格利塔增加了铁硫和结合的硫分数,同时降低了具有和没有ATM的细胞中的cystathionine gamma-lyase活性.
皮奥格利塔在ATM缺乏细胞中增强了减少的谷氨和减少了DNA损伤,但在ATM野生类型细胞中没有.
这些发现很重要,因为铁硫,结合硫和减少的谷在心血管疾病中往往减少.

结论:

皮奥格利塔增强了铁硫聚合物和结合的硫分数,影响了硫化合成.
皮奥格利塔对有缺陷ATM蛋白信号传递的细胞具有有益作用.
这项研究确定了皮奥格利塔在与心血管健康相关的细胞过程中的新型药理作用.

关键词:

这是一个ATMATMATM.过敏症 - 过敏性脑膜炎硫化是一种硫化.铁-硫集群是一种铁-硫集群.美国国家金融服务体系 (NFS1)皮奥格利塔是如何使用的通过S-硫化.

相关概念视频

01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

240

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

240

01:23

Dipeptidyl Peptidase 4 Inhibitors

216

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

216

01:17

Oral Hypoglycemic Agents: Sulfonylureas

250

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...

250

01:06

Oral Hypoglycemic Agents: Glinides

190

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

190

01:14

Drug Metabolism: Phase II Reactions

3.9K

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...

3.9K

01:19

Phase II Reactions: Sulfation and Conjugation with α-Amino Acids

304

Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme...

304